Article Menu
- Academic Editor
- Subscribe SciFeed
- Recommended Articles
- Related Info Links
-
More by Authors Links
- on DOAJ
- Cafaro, A.
- Foca, F.
- Nanni, O.
- Chiumente, M.
- Coppola, M.
- Russi, A.
- Svegliati, E.
- Baldo, P.
- Orzetti, S.
- Enrico, F.
- Foglio, F.
- Pinnavaia, D.
- Ladisa, V.
- Lauria Pantano, C.
- Lerose, R.
- Nardulli, P.
- Ferraiuolo, S.
- Maiolino, P.
- De Stasio, I.
- Gradellini, F.
- Gasbarro, A. Rita
- Santeramo, R.
- Carrucciu, G.
- Provasi, R.
- Cirino, M.
- Cappelletto, P. Cristina
- Fonzi, E.
- Pasqualini, A.
- Vecchia, S.
- Veraldi, M.
- De Francesco, A. Emanuela
- Crinò, L.
- Delmonte, A.
- Masini, C.
- on Google Scholar
- Cafaro, A.
- Foca, F.
- Nanni, O.
- Chiumente, M.
- Coppola, M.
- Russi, A.
- Svegliati, E.
- Baldo, P.
- Orzetti, S.
- Enrico, F.
- Foglio, F.
- Pinnavaia, D.
- Ladisa, V.
- Lauria Pantano, C.
- Lerose, R.
- Nardulli, P.
- Ferraiuolo, S.
- Maiolino, P.
- De Stasio, I.
- Gradellini, F.
- Gasbarro, A. Rita
- Santeramo, R.
- Carrucciu, G.
- Provasi, R.
- Cirino, M.
- Cappelletto, P. Cristina
- Fonzi, E.
- Pasqualini, A.
- Vecchia, S.
- Veraldi, M.
- De Francesco, A. Emanuela
- Crinò, L.
- Delmonte, A.
- Masini, C.
- on PubMed
- Cafaro, A.
- Foca, F.
- Nanni, O.
- Chiumente, M.
- Coppola, M.
- Russi, A.
- Svegliati, E.
- Baldo, P.
- Orzetti, S.
- Enrico, F.
- Foglio, F.
- Pinnavaia, D.
- Ladisa, V.
- Lauria Pantano, C.
- Lerose, R.
- Nardulli, P.
- Ferraiuolo, S.
- Maiolino, P.
- De Stasio, I.
- Gradellini, F.
- Gasbarro, A. Rita
- Santeramo, R.
- Carrucciu, G.
- Provasi, R.
- Cirino, M.
- Cappelletto, P. Cristina
- Fonzi, E.
- Pasqualini, A.
- Vecchia, S.
- Veraldi, M.
- De Francesco, A. Emanuela
- Crinò, L.
- Delmonte, A.
- Masini, C.
Need Help?
Order Article Reprints
Journal: Cancers, 2024
Volume: 16
Number: 1802
1802
Article:
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)
Authors:
by
Alessandro Cafaro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Alberto Russi, Elena Svegliati, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, Federico Foglio, Davide Pinnavaia, Vito Ladisa, Claudia Lauria Pantano, Rosa Lerose, Patrizia Nardulli, Simona Ferraiuolo, Piera Maiolino, Immacolata De Stasio, Federica Gradellini, Anna Rita Gasbarro, Rossella Santeramo, Gisella Carrucciu, Riccardo Provasi, Mario Cirino, Paola Cristina Cappelletto, Elisabetta Fonzi, Alessandra Pasqualini, Stefano Vecchia, Marianna Veraldi, Adele Emanuela De Francesco, Lucio Crinò, Angelo Delmonte and Carla Masiniadd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/16/10/1802
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Cafaro, A.; Foca, F.; Nanni, O.; Chiumente, M.; Coppola, M.; Russi, A.; Svegliati, E.; Baldo, P.; Orzetti, S.; Enrico, F.; et al. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study). Cancers 2024, 16, 1802. https://doi.org/10.3390/cancers16101802
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, et al. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study). Cancers. 2024; 16(10):1802. https://doi.org/10.3390/cancers16101802
Chicago/Turabian StyleCafaro, Alessandro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Alberto Russi, Elena Svegliati, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, and et al. 2024. "Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)" Cancers 16, no. 10: 1802. https://doi.org/10.3390/cancers16101802
APA StyleCafaro, A., Foca, F., Nanni, O., Chiumente, M., Coppola, M., Russi, A., Svegliati, E., Baldo, P., Orzetti, S., Enrico, F., Foglio, F., Pinnavaia, D., Ladisa, V., Lauria Pantano, C., Lerose, R., Nardulli, P., Ferraiuolo, S., Maiolino, P., De Stasio, I., ... Masini, C. (2024). Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study). Cancers, 16(10), 1802. https://doi.org/10.3390/cancers16101802
